

**Projects carried out since 2020**  
(only projects for which the Principal Investigator is/was from the Institute of  
Pharmacology are listed)

**Projects supported by the National Grant Agencies**

**APVV**

Cell interactions in the tumour microenvironment and their pharmacological modulations.  
APVV-16-0446;

Principal Investigator: RNDr. Lenka Varinská, PhD./prof. MVDr. Ján Mojžiš, DrSc

Biocompatibility assessment of new generation lipophosphonoxins for wound infection  
management. APVV-22-0006;

Principal Investigator: RNDr. Gál Peter, DrSc.

**VEGA**

Fibroblasts and tumor microenvironment: cell interactions and their pharmacological  
modulation. VEGA 1/0539/21;

Principal Investigator: prof. MVDr. Mojžiš Ján, DrSc.

Clinical relevance of programmed-death (PD) receptor expression in the microenvironment  
of breast carcinomas. VEGA 1/0513/21;

Principal Investigator: prof. MUDr. Mirossay Ladislav, DrSc.

Modulation of the tumor microenvironment in breast cancer by lichen secondary  
metabolites: an in vitro study. VEGA 1/0498/23;

Principal Investigator: Kello Martin, PhD.

SLAMF receptors in chronic lymphocytic leukemia – potential targets for anticancer therapy.  
VEGA 1/0617/22;

Principal Investigator: PharmDr. Šarišský Marek, PhD.

Study of chalcones in the context of their effects on membrane transporters responsible for  
drug resistance. VEGA 1/0446/22;

Principal Investigator: doc. MUDr. Martina Čižmáriková, PhD.

Development of an active wound dressing based on an antibacterial (LPP0) hydrogel  
containing a plant extract that stimulates wound healing. VEGA 1/0455/22.

Principal Investigator: RNDr. Gál Peter, DrSc.

**Ongoing since 2026**

Pharmacogenetic aspects of antidepressant therapy: The significance of P-glycoprotein gene  
variants and other genetic determinants in the Slovak population. VEGA 1/0123/26

Principal Investigator: doc. MUDr. Martina Čižmáriková, PhD.

Innovative approaches to glioblastoma therapy: Combination of natural compounds and biocompatible nanoparticles in 3D models. VEGA 1/0210/26.

Principal Investigator: PharmDr. Radka Michalková, PhD.

Study of the role of hyaluronic acid and yarrow (*Achillea millefolium*) extracts in skin regeneration and wound healing. VEGA 1/0185/26

Principal Investigator: RNDr. Gál Peter, DrSc.

## **VVGS**

Analysis of the expression of SLAM-associated proteins SAP and EAT-2 in B cells. VVGS- 2020-1652; Principal Investigator: Mgr. Huniadi Mykhailo

A new innovative strategy in cancer treatment: natural compounds and mechanisms of autophagy regulation – an in vitro study. VVGS-2020-1666;

Principal Investigator: PharmDr. Michalková Radka

Galectins – their relationship to ABC transporter expression and their potential modulation by acridine-derived chalcones. VVGS-2023-2754.

Principal Investigator: PharmDr. Franko Ondrej

## **Projects supported by EU**

### **Structural Funds**

Open scientific community for modern interdisciplinary research in medicine (OPENMED).

Principal Investigator of the Activity 7.1: prof. MVDr. J. Mojžiš, DrSc.

### **Recovery and Resilience Plan for Slovakia**

Uncovering the impact of heterogeneity of tumor-associated fibroblasts on chemosensitivity of pancreatic ductal adenocarcinoma PO: Component 9– ÚV SR (09I03-03-V04-00398) – (R2).

Principal Investigator: RNDr. Matúš Čoma, PhD.

Uncovering the biocompatibility of lipofosfonoxins for wound infection management:

Towards a new generation of therapeutics. PO: Component 9– ÚV SR (09I03-03-V04-00075) (R3);

Principal Investigator: RNDr. Gál Peter, DrSc.